HARA MASAKI1,2, ANDO MINORU1, NOKIBA HIROHIKO1, MORITO TAKU1, TSUCHIYA KEN2, NITTA KOSAKU2 1Renal Division, Department Regorafenib ic50 of Medicine, Tokyo Metropolitan Cancer Center, Komagome Hospital; 2Department IV of Internal Medicine, Tokyo Women’s Medical University Introduction: Gemcitabine (Gem)

is a widely used nucleoside analog approved for treatment of several types of cancers. Gem administration is known to induce glomerular thrombotic microangiopathy, resulting in the emergence of proteinuria and/or kidney dysfunction. This study was undertaken to ascertain both incidence of proteinuria and an association between incident proteinuria and mortality in Gem recipients. Methods: A prospective cohort study was conducted in 67 non-proteinuric patients with pancreatic or biliary cancer (35 men, mean age, 68 years), Epigenetics inhibitor who received the first mono-therapy of Gem and who lived more than 6 months. Incident proteinuria was defined as dipstick test ≥1 +, persistent in at least two consecutive examinations within 6 months following Gem administration. Cumulative mortality was analyzed by the Kaplan-Meier method,

stratified by presence and absence of incident proteinuria. Multivariable Cox proportional hazards regression analysis was used to calculate hazard ratio (HR) with its 95% confidence interval (CI) for all-cause mortality, adjusted for age, gender, stages of the disease, and estimated glomerular filtration rate (eGFR). Results: Incidence of proteinuria was 25.3% in the first 6 months, and mortality rate was 65.7% in the follow-up period (median, 393; range, 184–1004

days). Cumulative mortality was significantly greater in patients who developed proteinuria (65.2%) than those who did not (36.6%) at the time of 393 days following the Gem administration. [figure]. The HR (95% CI) of proteinuria incidence for mortality was 2.60 (1.24–5.24; P = 0.0126), as compared with the opponent. [table]. Conclusion: Incidence of proteinuria may be a harbinger of near-term death in Gem recipients. SHANMUGAM VIJAY, G, ABRAHAM GEORGI, Selleck Etoposide VEERAPPAN ILANGOVAN, SINGH TRIPAT, DAS SUBASHIS Pondicherry Institute of Medical Sciences Introduction: Obstructive sleep apnea is the most common form of apnea and is due to repeated episodes of complete or partial blockage of the upper airway during sleep.This study assesses the prevalence of obstructive sleep apnea in chronic kidney disease among south Indian population. Methods: This cross sectional study population was divided into two groups group with group 1 or the early CKD group population comprising of CKD patients with GFR ranging from 30–89 ml/min and group 2 or the late CKD group population comprising if patients with GFR ranging from 15–29 ml/min.